ROIV

Roivant Sciences Ltd.

A biopharmaceutical company that develops experimental drugs for autoimmune and rare diseases through a family of nimble subsidiaries it calls 'Vants' — including Immunovant, Priovant, and Pulmovant — each focused on a specific drug candidate. Founded in 2014 by entrepreneur Vivek Ramaswamy, the name blends 'ROI' (return on investment) with the '-vant' suffix stamped on every subsidiary. Its most advanced candidate, brepocitinib, is under FDA review for the rare muscle disease dermatomyositis.